Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “SLN360 is a double-stranded small interfering ribonucleic acid (siRNA) targeting LPA messenger RNA (mRNA)”In the company’s words, NCT05537571 on ClinicalTrials.gov
- Tested for
- Cardiovascular Diseases, Atherosclerosis, Lipoprotein(a), Hyperlipidemias, Dyslipidemias, Elevated Lp(a)
- Main trialPhase 2
- “Phase 2 study to evaluate the efficacy, safety and tolerability of SLN360 administered subcutaneously (SC) compared with placebo in adult participants with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events”In the company’s words, NCT05537571 on ClinicalTrials.gov
- Other names
- Zerlasiran
Other drugs for Cardiovascular Diseases
- MezigdomideCelgene · Phase 3
- Neuroncell-EXCytopeutics Sdn. Bhd. · Phase 2/3
- ObicetrapibNewAmsterdam Pharma · Phase 3
- MilvexianJohnson & Johnson (Janssen) · Bristol Myers Squibb · Phase 3
- BaxdrostatAstraZeneca · Phase 3
- VicagrelJiangsu vcare pharmaceutical technology co., LTD · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 11 Jan 2024 | Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events | |
| Phase 1Completed | 23 Aug 2023 | Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026